{"disease":{"id":"metastatic-breast-cancer-hr","name":"metastatic breast cancer hr"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07318805","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT07156253","title":"Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT04448886","title":"Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Ana C Garrido-Castro, MD","has_results":true},{"nct_id":"NCT07088588","title":"Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":105,"lead_sponsor_name":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT06774027","title":"Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06666270","title":"Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}